Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Jiangsu HengRui Medicine Co., Ltd.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Gilead Sciences
AstraZeneca
AstraZeneca
Wake Forest University Health Sciences
Big Ten Cancer Research Consortium
Mayo Clinic
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
BeiGene
Masonic Cancer Center, University of Minnesota
Mirati Therapeutics Inc.
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Bristol-Myers Squibb
Fundación GECP
EpicentRx, Inc.
Hoosier Cancer Research Network
Massachusetts General Hospital
BeiGene
Centre Leon Berard
Sichuan University
Spanish Lung Cancer Group
Nanfang Hospital, Southern Medical University
SCRI Development Innovations, LLC
University of Washington
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
University of Washington
Barbara Ann Karmanos Cancer Institute
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Swiss Cancer Institute
University of California, San Francisco
Sun Yat-sen University
Chonnam National University Hospital
Duke University
Eli Lilly and Company
SWOG Cancer Research Network
Zhejiang Cancer Hospital
Eli Lilly and Company
Eli Lilly and Company
Leo W. Jenkins Cancer Center
Radiation Therapy Oncology Group